Ocean Biomedical, Inc. Joins the Russell 2000® Index
27 juin 2023 08h01 HE
|
Ocean Biomedical, Inc.
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria ...
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
27 juin 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
15 juin 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
02 juin 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...
Kinarus Therapeutics Group Reports 2022 Annual Results
31 mai 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Publishes Annual Report with Audited Consolidated Financial Results for Year Ended 31 December 2022Clinical efforts re-focused on developing KIN001 for original indications IPF and wet AMDCDIM CHF1.5...
Idiopathic Pulmonary Fibrosis Market to Surpass US$ 7,521.2 Million by 2030, Says Coherent Market Insights (CMI)
25 mai 2023 09h01 HE
|
CMI
Burlingame, May 25, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global idiopathic pulmonary fibrosis market is estimated to be valued at US$ 3,853.6 million in 2022 and is...
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
23 mai 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today presented...
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
11 mai 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
FibroGen Reports First Quarter 2023 Financial Results
08 mai 2023 16h01 HE
|
FibroGen, Inc.
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
05 mai 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Audited full year 2022 annual financial figures due to be reported by end of May 2023 Basel, Switzerland, May 5, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage...